Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Big pharma interest remains, but the mood is fast turning gloomy.
So who else could be interested in the oestrogen degrader?
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
The recently unveiled conjugate DS3610a is to start phase 1.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
